Cost-effectiveness evaluations based on clinical trial data on IDegLira indicate that it is likely to improve clinical outcomes and be cost-effective compared to several comparator regimens (basal insulin, basal-bolus insulin, and GLP-1 receptor agonists in combination with insulin) in patients with type 2 diabetes in the United States, the Netherlands, the Czech Republic, Sweden, the United Kingdom, and Spain [23, 34–38]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.